 Erdheim-Chester Disease
"Erdheim-Chester Disease" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A rare form of non-Langerhans-cell histiocytosis (HISTIOCYTOSIS, NON-LANGERHANS-CELL) with onset in middle age. The systemic disease is characterized by infiltration of lipid-laden macrophages, multinucleated giant cells, an inflammatory infiltrate of lymphocytes and histiocytes in the bone marrow, and a generalized sclerosis of the long bones.
| Descriptor ID |
D031249
|
| MeSH Number(s) |
C15.604.250.410.224
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Erdheim-Chester Disease".
Below are MeSH descriptors whose meaning is more specific than "Erdheim-Chester Disease".
This graph shows the total number of publications written about "Erdheim-Chester Disease" by people in UAMS Profiles by year, and whether "Erdheim-Chester Disease" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2023 | 2 | 0 | 2 | | 2022 | 2 | 0 | 2 | | 2021 | 1 | 0 | 1 | | 2019 | 2 | 0 | 2 | | 2018 | 1 | 0 | 1 | | 2017 | 1 | 0 | 1 | | 2016 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Erdheim-Chester Disease" by people in Profiles over the past ten years.
-
Dai JW, Lin H, Chang L, Li J, Zhou DB, Cao XX. The clinical spectrum and prognostic factors of Erdheim-Chester disease and mixed Langerhans cell histiocytosis and Erdheim-Chester disease. Ann Hematol. 2023 Dec; 102(12):3335-3343.
-
Portegys J, Heidemeier A, Rosenwald A, Gernert M, Fr?hlich M, Hueper S, Strunz PP, Rasche L, Schmalzing M. Erdheim-Chester disease with Rosai-Dorfman-like lesions: treatment with methotrexate, anakinra and upadacitinib. RMD Open. 2023 01; 9(1).
-
Zhao AL, Cai H, Chen J, Duan MH, Zhou DB, Li J, Cao XX. The potential of cell-free DNA to reveal the molecular profiles of Langerhans cell histiocytosis and Erdheim-Chester disease in adults. Leukemia. 2022 05; 36(5):1412-1415.
-
Liu T, Cai HC, Cai H, Chen M, Zhang W, Li J, Zhou DB, Cao XX. Intermediate-dose cytarabine is an effective therapy for adults with non-Langerhans cell histiocytosis. Orphanet J Rare Dis. 2022 02 07; 17(1):39.
-
Wang JN, Wang FD, Sun J, Liang ZY, Li J, Zhou DB, Tian X, Cao XX. Pulmonary manifestations of Erdheim-Chester disease: clinical characteristics, outcomes and comparison with Langerhans cell histiocytosis. Br J Haematol. 2021 09; 194(6):1024-1033.
-
Wang JN, Qiu Y, Niu N, Zhang Y, Li J, Zhou DB, Cao XX. Successful treatment of central nervous system involved Erdheim-Chester disease by intermediate-dose cytarabine as first-line therapy. Acta Oncol. 2020 Mar; 59(3):302-305.
-
Cao XX, Niu N, Sun J, Cai H, Wang FD, Wang YN, Duan MH, Zhou DB, Li J. Clinical and positron emission tomography responses to long-term high-dose interferon-a treatment among patients with Erdheim-Chester disease. Orphanet J Rare Dis. 2019 01 10; 14(1):11.
-
Zhao AL, Wang YN, Wang FD, Niu N, Sun J, Mao YY, Zhou DB, Li J, Cao XX. Successful Treatment of Erdheim-Chester Disease With Coronary Artery Involvement. Can J Cardiol. 2018 12; 34(12):1688.e9-1688.e11.
-
Cao XX, Niu N, Sun J, Zhou DB, Li J. Efficacy of intermediate-dose cytarabine in central nervous system-relapsed wild-type BRAF Erdheim-Chester disease. Ann Hematol. 2018 Jan; 97(1):185-187.
-
Cao XX, Sun J, Li J, Zhong DR, Niu N, Duan MH, Liang ZY, Zhou DB. Evaluation of clinicopathologic characteristics and the BRAF V600E mutation in Erdheim-Chester disease among Chinese adults. Ann Hematol. 2016 Apr; 95(5):745-50.
|
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|